Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct;52(Pt 2):117-124.
doi: 10.1016/j.semcancer.2017.12.002. Epub 2017 Dec 8.

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

Priti S Hegde  1 , Jeffrey J Wallin  2 , Christoph Mancao  2
Affiliations
Review

Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

Priti S Hegde et al. Semin Cancer Biol. 2018 Oct.

Abstract

The critical role of angiogenesis in promoting tumor growth and metastasis has been well established scientifically, and consequently blocking this pathway as a therapeutic strategy has demonstrated great clinical success for the treatment of cancer. The holy grail however, has been the identification of patients who derive significant survival benefit from this class of agents. Here we attempt to delineate the diverse mechanisms related to anti-VEGF including its role as an anti-vascular, anti-angiogenic or an anti-permeability factor and review the most promising predictive biomarkers interrogated in large clinical trials, that identify patients who may derive significant survival advantage with VEGF inhibition. Lastly, we describe the function of VEGF as an immunomodulator and illustrate the evidence for anti-VEGF in reprogramming the tumor milieu from an immunosuppressive to an immune permissive microenvironment in human cancers, thus elucidating the role of anti-VEGF as an optimal combination partner for immune checkpoint inhibitors.

Keywords: Angiogenesis; CTLA4; Cancer immunity; Clinical trials; Immunotherapy; Inflammation; PD-L1/PD-1; Predictive biomarkers; VEGF.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

Substances